ArticleEndocrine2025
Global, regional, and national burden and trends of Type 2 diabetes mellitus among women of childbearing age from 1990 to 2021, with projections to 2030: a systematic analysis for the Global Burden of Disease Study 2021.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A nonlinear, causal link between serum 25-hydroxyvitamin D and prolactin in type 2 diabetes: Evidence from clinical and Mendelian randomization analyses.Metabolism open · 2025Article
- A ZIF-8-Based High-Performance Glucose Electrochemical Detection Platform Constructed Using a Multi-Layer Interface Optimization Strategy.Sensors (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveType 2 diabetes mellitus (T2DM) constitutes a severe public health issue among women of childbearing age (WCBA) globally. This study aimed to investigate the epidemiological characteristics of T2DM among WCBA from 1990 to 2021, with projections until 2030.
methodsWe used estimates from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 concerning the prevalence, mortality, and disability-adjusted life years (DALYs) of T2DM in WCBA aged 15-49 years across 21 regions and 204 countries and territories from 1990 to 2021. Based on Joinpoint regression models, disease trends were depicted using Annual Percent Change (APC) and Average Annual Percent Change (AAPC). Spearman correlation was employed to assess the correlation between T2DM burden and sociodemographic index (SDI). Bayesian age-period-cohort model projected the epidemiological trajectories up to 2030.
resultsIn 2021, there were 73,858,922 prevalent cases, 42,106 mortalities, and 6,895,581 DALYs of T2DM among WCBA globally. From 1990 to 2021, global age-standardized prevalence, mortality, and DALYs rates have increased, with AAPC of 2.46, 0.21, and 1.62, respectively. In terms of age, in 2021, the burden associated with T2DM mainly affected WCBA aged 45-49 years old. At both regional and national levels, the age-standardized mortality and DALY rates for T2DM were found to be negatively correlated with the SDI (All P < 0.001). Projection modeling showed that more WCBA were expected to develop T2DM by 2030.
conclusionT2DM remains an ongoing public health challenge, especially in lower SDI regions and older WCBA.
Indexed as
Identifiers
40634821What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.